Delivering the right medicine, to the right patient, at the right time.
Clinigen is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines.
1. Culture: Develop and retain talented people
2020 Progress
- 36 employees completed the Clinigen Management Academy training program
- Launched online recruitment platform
- Launched global wellbeing program
Performance Metrics
- Employee engagement score: 7.5
2021 Objectives
- Integrate culture and values across the Group
- Implement a global HR system
- Develop a strategic resourcing plan
- Improve people management capabilities
2. Technology: Upgrade technology platform to drive organic growth
2020 Progress
- Launch of Clinigen One ERP in UK and US
- Growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact with the customer
- Clinigen Direct localised for four markets
- UK drug shortages tracker launched
- Relaunch of FDA-compliant Proleukin US website
Performance Metrics
- Number of products available on Cliniport and Clinigen Direct: >2,600
2021 Objectives
- Regionally based customer services
- Enhanced online ordering platform for Managed Access and ‘on-demand’ businesses in Unlicensed Medicines and for Commercial Medicines
- Enhanced UK online ordering platform for QPL and Aseptics businesses in Unlicensed Medicines
3. Customer: Expand and embed a global community of HCPS and opinion leaders
2020 Progress
- Increase in number of MAPs and exclusive Global Access client supply agreements driving growth of Cliniport (proprietary web-based operating system) enabling the Group to better interact
with the customer - Clinigen Direct localised for four markets
- Relaunch of FDA-compliant Proleukin US website
Performance Metrics
2021 Objectives
- Increase number of users and amount of activity through Cliniport and Clinigen Direct
- Expand MSL and commercial capability in the US and the EU
- Drive Key Opinion Leader (‘KOL’), hospital pharmacist and pharmacy group engagement across markets
4. Business: Expand portfolio of global, regional and licensed assets
2020 Progress
- Exclusive global licensing and distribution agreement signed with PBL to commercialise Erwinase strengthens commercial offering in key markets
- Collaboration with GC Pharma in Japan to submit new drug application for Hunterase
- Exclusive agreement signed with Cheplapharm in Australia and New Zealand to distribute Etopophos and Vepesid
- Internationalisation of Developed Products portfolio
Performance Metrics
2021 Objectives
- Further conversion of UL2L pipeline
- Further internationalisation of Developed Product portfolio
- Continue to search for selective acquisitions and in-licensing agreements
- Conversion of MAPs to regional licensing opportunities
5. Business: Become the 'go to' global leader in ethical access to unlicensed medicines
2020 Progress
- EU entity established to maximise ‘on-demand’ opportunity
- Increase in number of MAPs and exclusive Global Access client supply agreements
- ‘Shortage Scramble Team’ established to maximise the opportunity in fulfilling global drug shortages
- Rapidly flexed resources and efforts to react to COVID-19 related MAPs and Global Access ‘on-demand’ opportunity
Performance Metrics
2021 Objectives
- Expand and deepen our client base in Managed Access
- Grow and develop our portfolio of exclusive supply agreements
- Drive growth in EU entity by developing portfolio, pricing and customer experience in key EU markets
- Build RWD capability to provide a differentiated service to clients
- Ensure smooth delivery of enhanced digital ordering platforms
6. Business: Extend global footprint into remaining key markets
2020 Progress
- Exclusive global licensing and distribution agreement signed with Porton
Biopharma to commercialise Erwinase strengthens commercial offering in key markets - Internationalisation of Developed Products portfolio
Performance Metrics
2021 Objectives
- Further partnership agreements signed to expand geographical reach,
particularly in the LATAM and the Middle East - Further expansion of commercial infrastructure in US and EU
7. Business: Link to Businesses to realise synergistic opportunities and increase pharmaceutical customer base
2020 Progress
- Increase in the number of pharmaceutical and biotech companies working with all business operations
- iQone supporting implementation and management of MAPs
- Cross-divisional referrals driving pipeline and leading to new business wins
Performance Metrics
- Number of pharmaceutical and biotech companies who have worked with all three business operations: 8
2021 Objectives
- Increase the number of pharmaceutical and biotech companies working with all business operations
- Increase the number of companies working with at least two business operations
- Increase the number of top 50 companies in which the Group has a relationship
- Secure new business wins by moving a client or molecule through Clinigen’s lifecycle platform